Dramatic PSA Increase With Tumor Shrinkage After Initiating Degarelix in Advanced Prostate Cancer.
Roswell Park Cancer Institute, Buffalo, NY. Electronic address: Nischala.Ammannagari@Roswellpark.org.
Nischala
N
Ammannagari
University of Buffalo, Buffalo, NY.
Chandana
C
Javvaji
Roswell Park Cancer Institute, Buffalo, NY.
Pongwut
P
Danchaivijitr
Roswell Park Cancer Institute, Buffalo, NY.
Saby
S
George
D000230:Adenocarcinoma / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary; D000077143:Docetaxel; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D011859:Radiography; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects
D009842:Oligopeptides; D043823:Taxoids; C431566:acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; D000077143:Docetaxel; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen
Degarelix; GnRH antagonists; PSA rise; Prostate cancer; Tumor lysis